> 定義

# AORTIC ANEURYSMS

### 定義

• **True** aneurysm (≥50% dilation of all 3 layers of aorta) vs. **false** (rupture within adventitia)

• **Location:** root (annuloaortic ectasia), thoracic aortic aneurysm (TAA), thoracoabdominal aortic aneurysm (TAAA), abdominal aortic aneurysm (AAA)

• **Type:** fusiform (circumferential dilation) vs. saccular (localized dilation of aortic wall)

### 流行病學 (_Circ_ 2010;121:e266, 2011;124:2020; _Nat Rev Cardiol_ 2011;8:92)

• **TAA:** ♂:♀ 2:1; ~60% root/ascending; 40% desc.

• **AAA:** ~4–8% prev in those >60 y; 5× more common in ♂; mostly infrarenal

### 病生理 & risk factors (_NEJM_ 2009;361:1114; _Nat Med_ 2009;15:649)

• Medial degen and/or ↑ wall stress; wall stress ∝ \[(∆P × r) / (wall thickness)\] (Laplace’s law)

• **TAA:** medial degeneration (muscle apoptosis, elastin fiber weakening); a/w CTD, aortitis

• **AAA:** long-standing HTN + athero/inflammation → medial weakening

• Classic **臨床risk factors:** HTN, atherosclerosis, smoking, age, ♂

• **CTD** (Marfan, Ehlers-Danlos type IV, Loeys-Dietz); **congenital** (bicuspid AoV, Turner’s) **aortitis** (Takayasu’s GCA, spondyloarthritis, IgG4, syphilis); trauma

### Screening (_Circ_ 2010;121:e266 & 2011;124:2020; _Annals_ 2014;161:281; _JAMA_ 2015;313:1156)

• **TAA:** if bicuspid AoV or 1° relative with: (a) TAA or bicuspid AoV, (b) CTD as above

• **AAA:** ✔ for pulsatile abd mass; U/S ♂ >60 y with FHx of AAA & ♂ 65–75 y with prior tobacco

### Diagnostic studies (_Circ_ 2010;121:e266 & 2011;124:2020)

• **Contrast CT:** quick, noninvasive, high Se & Sp for all aortic aneurysms

• **TTE/TEE:** TTE most useful for root and proximal Ao; TEE can visualize other sites of TAA

• **MRI:** favored over CT for AoRoot imaging; useful in AAA but time consuming; noncontrast “black blood” MR to assess aortic wall

• **Abdominal U/S:** screening/surveillance test of choice for infrarenal AAA

### 治療 (_Circ_ 2008;117:1883 & 2010;121:e266 & 2016;133:680; _NEJM_ 2014;371:2101)

• Goal is to prevent rupture (50% mortality prior to hospital) by modifying risk factors

• **Risk factor modification:** smoking cessation; LDL-C <70–100 mg/dl

• **BP control: βB** (↓ dP/dt) ↓ aneurysm growth (_NEJM_ 1994;330:1335); **ACEI** a/w ↓ rupture risk (_Lancet_ 2006;368:659); **ARB** may ↓ rate of aortic root growth in Marfan (_NEJM_ 2008;358:2787)

• Mod CV exercise OK, no burst activity requiring Valsalva maneuvers (eg, heavy lifting)

• **Indications for surgery** (individualized based on FHx, body size, gender, anatomy)

**TAA:** 症狀s; ascending Ao ≥5.5 cm (4–5 cm if Marfan, L-D, EDS, bicuspid AoV); descending Ao >6 cm; ≥4.5 cm and planned AoV surgery; ↑ >0.5 cm/y

**AAA:** 症狀; infrarenal >5.5 cm; consider ≥5.0 cm in ♀; ↑ >0.5 cm/y; inflam/infxn

### Endovascular repair (EVAR) (_NEJM_ 2008;358:494; _Circ_ 2011;124:2020 & 2015;131:1291)

• Requires favorable aortic anatomy

• **TEVAR** (thoracic EVAR) for descending TAA ≥5.5 cm may ↓ periop morbidity and possibly mortality (_Circ_ 2010;121:2780; _JACC_ 2010;55:986; _J Thorac CV Surg_ 2010;140:1001 & 2012;144:604)

• **AAA:** guidelines support open repair or EVAR for infrarenal AAA in good surg candidates

↓ short-term mort., bleeding, LOS; but long-term graft complic. (3–4%/y; endoleak, need for reintervention, rupture) necessitate periodic surveillance, with no difference in mortality long term (_Lancet_ 2016;388:2366; _NEJM_ 2019;380:2126)

In 病人 unfit for surgery or high periop risks: ↓ aneurysm-related mortality but no ∆ in overall mortality over med Rx (_NEJM_ 2010;362:1872). EVAR noninferior (? superior) to open repair in ruptured AAA with favorable anatomy (_Ann Surg_ 2009;250:818).

### Complications (_Circ_ 2010;121:e266; _Nat Rev Cardiol_ 2011;8:92)

• **Pain:** gnawing chest, back, or abdominal pain; new or worse pain may signal rupture

• **Rupture:** risk ↑ with diameter, ♀, current smoking, HTN

**TAA:** ~2.5%/y if <6 cm vs. 7%/y if >6 cm

**AAA:** ~1%/y if <5 cm vs. 6.5%/y if 5–5.9 cm; ~80% mortality at 24 h

• **Aortic insufficiency (TAA)**, **CHF, acute aortic syndromes** (qv)

• **Thromboembolic ischemic events** (eg, to CNS, viscera, extremities)

• **Compression of adjacent structures** (eg, SVC, trachea, esophagus, laryngeal nerve)

### Follow-up (_Circ_ 2010;121:e266; _Nat Rev Cardiol_ 2011;8:92; _JAMA_ 2013;309:806)

• Expansion rate ~0.1 cm/y for TAA, ~0.3–0.4 cm/y for AAA

• AAA: <4 cm q2–3y; 4–5.4 cm q6–12mo; more often if rate of expansion >0.5 cm in 6 mo

• TAA: 6 mo after dx to ensure stable, and if stable, then annually (_Circ_ 2005;111:816)

• Screen for CAD, PAD, and aneurysms elsewhere, espec popliteal. About 25% of 病人 with TAA will also have AAA, and 25% of AAA 病人 will have a TAA: consider pan-Ao imaging.
